<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6705">
  <stage>Registered</stage>
  <submitdate>5/09/2017</submitdate>
  <approvaldate>5/09/2017</approvaldate>
  <nctid>NCT03276858</nctid>
  <trial_identification>
    <studytitle>Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers</studytitle>
    <scientifictitle>Single- And-Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam Pharmacokinetics</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRN00808-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CRN00808
Treatment: drugs - Placebo Oral Solution
Treatment: drugs - Midazolam oral solution
Treatment: drugs - Placebo oral capsule

Experimental: CRN00808 Oral Solution - CRN00808 oral solution, single-dose

Experimental: CRN00808 Oral Capsule - CRN00808 oral capsule, single-dose and multiple-doses

Placebo Comparator: Placebo Oral Solution - Placebo oral solution, single-dose

Placebo Comparator: Placebo Oral Capsule - Placebo oral capsule, single-dose and multiple doses

Other: Midazolam Oral Solution - Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study


Treatment: drugs: CRN00808
Investigational drug

Treatment: drugs: Placebo Oral Solution
Placebo

Treatment: drugs: Midazolam oral solution
Midazolam as part of the drug-drug interaction arm of the study

Treatment: drugs: Placebo oral capsule
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 single ascending doses using clinical assessments, telemetry, and Holter monitoring and subject self-reporting - ECG, clinical laboratory parameters, vital signs, physical examinations, telemetry, Holter monitoring</outcome>
      <timepoint>Day 1 through Day 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 multiple ascending doses using clinical assessments and subject self-reporting - ECG, clinical laboratory parameters, vital signs, physical examinations</outcome>
      <timepoint>Day 1 through Day 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>AUC of CRN00808 single ascending doses - plasma AUC</outcome>
      <timepoint>Day 1 through Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax of CRN00808 single ascending doses - plasma Cmax</outcome>
      <timepoint>Day 1 through Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>t1/2 of CRN00808 single ascending doses - plasma t1/2</outcome>
      <timepoint>Day 1 through Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tmax of CRN00808 single ascending doses - plasma Tmax</outcome>
      <timepoint>Day 1 through Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUC of CRN00808 multiple ascending doses - plasma AUC</outcome>
      <timepoint>Day 1 through Day 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax of CRN00808 multiple ascending doses - plasma Cmax</outcome>
      <timepoint>Day 1 through Day 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>t1/2 of CRN00808 multiple ascending doses - plasma t1/2</outcome>
      <timepoint>Day 1 through Day 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tmax of CRN00808 multiple ascending doses - plasma Tmax</outcome>
      <timepoint>Day 1 through Day 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics of CRN00808 in single ascending dose cohorts assessed by GHRH analog stimulated GH levels - Suppression of serum GH induced by a GH secretagogue</outcome>
      <timepoint>Day -1 and Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of CRN00808 on pharmacokinetics of midazolam - midazolam plasma AUC</outcome>
      <timepoint>Day 1 through Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of CRN00808 on Cmax of midazolam - midazolam plasma Cmax</outcome>
      <timepoint>Day 1 through Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of CRN00808 on t1/2 of midazolam - midazolam plasma t 1/2</outcome>
      <timepoint>Day 1 through Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of CRN00808 on Tmax of midazolam - midazolam plasma Tmax</outcome>
      <timepoint>Day 1 through Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relative bioavailability of capsule formulation - single-dose crossover arm only</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of food on Cmax of CRN00808 - plasma Cmax compared with and without food in single dose arm</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of food on AUC of CRN00808 - Plasma AUC compared with and without food in single dose arm</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics of CRN00808 in multiple ascending dose cohorts assessed by serum IGF-1 and GH - serum IGF-1 and GH</outcome>
      <timepoint>Day -1 to Day 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  BMI 18 to 30 kg/m2

          -  Females postmenopausal or surgically sterile</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any uncontrolled or active major systemic disease including, but not limited to:
             pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological,
             psychiatric, or neoplastic disorder with metastatic potential

          -  History or presence of malignancy within the past 5 years. Subjects who have been
             successfully treated (for 3 months or longer) with no recurrence of basal or squamous
             cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.

          -  Use of any investigational drug within the past 60 days or 5 half-lives, whichever is
             longer

          -  Have a medically significant abnormality observed during screening or the admission
             physical examination or in any other baseline measurements

          -  Use of any prior medication without approval of the investigator within 14 days prior
             to admission

          -  Tested positive at screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis
             C antibody (HCV-Ab) or has a history of a positive result

          -  History of alcohol or substance abuse in the past 6 months

          -  Any condition that in the opinion of the investigator would jeopardize the subject's
             appropriate participation in this Phase 1 study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>10/09/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>83</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Crinetics Pharmaceuticals Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This single-center study will be conducted in 3 phases: a single-ascending dose phase (up to
      6 cohorts, 8 subjects/cohort), a multiple-dose phase (up to 3 cohorts, 9 subjects/cohort),
      and a midazolam drug-drug interaction phase (one cohort of 8 subjects).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03276858</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jason Lickliter, MBBS PhD</name>
      <address>Nucleus Network</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Ajay Madan, PhD</name>
      <address />
      <phone>858-450-6464</phone>
      <fax />
      <email>amadan@crinetics.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>